Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fludarabine + cyclophosphamide
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Fludarabine + cyclophosphamide is a combination chemotherapy regimen primarily used in the treatment of B-cell chronic lymphocytic leukemia (CLL). Fludarabine is a purine analog antimetabolite that inhibits DNA synthesis by interfering with DNA polymerase alpha, ribonucleotide reductase, and DNA primase. Cyclophosphamide is an alkylating agent that crosslinks DNA strands and prevents cell division. The combination increases complete remission rates and reduces minimal residual disease compared to fludarabine alone. This regimen is often used as part of multi-drug protocols for CLL and other hematologic malignancies[2][5][8].
- Brand names
- FludaraCytoxan
- Other names
- FC regimenFLU-CY regimen
02
Targets
DNA-directed primase/polymerase protein (PrimPol)POLA1 (DNA polymerase alpha)RNR (Ribonucleotide reductase)DNA
Beyond the preview
Go deeper on Fludarabine + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fludarabine + cyclophosphamide.